BiotechTube
Zywie

Zywie

San Diego, United States· Est.
zywiebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Zywie is a private, preclinical-stage biotech founded in 2021 and based in San Diego, targeting Lysosomal Storage Diseases (LSDs) and related neurodegenerative disorders. Its core technology involves developing proprietary, modified versions of Ambroxol, a molecule with dual mechanisms of action as a pharmacological chaperone and a TFEB activator to enhance cellular clearance pathways. The company is led by veteran biotech entrepreneur Robert F. Johnston and is supported by a scientific advisory board with deep expertise in lysosomal biology and protein folding diseases. Zywie is currently in the pre-revenue, drug discovery and development phase.

Lysosomal Storage DiseasesNeurodegenerative Disorders

Technology Platform

Development of novel pharmacological chaperones based on deuterated and halogenated derivatives of Ambroxol, which stabilize misfolded proteins and activate TFEB to enhance lysosomal function and autophagy.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The multi-billion dollar LSD market is underserved, particularly for neurological manifestations, creating a significant opportunity for an effective oral therapy.
The platform's potential application in more common neurodegenerative diseases like Parkinson's (GBA1-related) offers a substantial expansion opportunity.
Creating novel chemical entities with strong IP provides a path to defensible, high-value assets.

Risk Factors

High scientific risk that novel Ambroxol derivatives will demonstrate superior efficacy and translate successfully from preclinical models to human trials.
Competitive landscape includes other modalities like gene therapy and ERTs.
As a pre-revenue, private company, it faces significant financial and operational risks, including dependence on future fundraising.

Competitive Landscape

Zywie competes in the LSD space with companies developing enzyme replacement therapies (e.g., Sanofi, Takeda), substrate reduction therapies, and gene therapies (e.g., Avrobio, Sangamo). In the pharmacological chaperone niche, it faces competition from companies like Amicus Therapeutics (which markets Galafold for Fabry disease) and others exploring similar approaches for different targets. Its differentiation lies in its specific IP around novel Ambroxol derivatives.

More companies in Small Molecule Drugs →More companies in United States →